Long-term application of MC903 in mice prolongs the characteristic symptoms of atopic dermatitis, such as inflammation, skin barrier dysfunction, and itching.

Atopic dermatitis (AD) is a chronic skin disease that causes itching and is characterized by recurrent flares and remissions. The interactions among type 2 inflammation, skin barrier dysfunction, and pruritus play important roles in the pathogenesis of AD. AD symptoms persist for a long period; thus, it is desirable to have disease models that reproduce a prolonged AD-like phenotype. Although MC903-induced AD model mice reportedly exhibit type 2 inflammation, skin barrier dysfunction, and pruritus, the effects of long-term application of MC903 on the changes in these symptoms over time are not fully understood. To clarify this point, we conducted a long-term time course analysis of these symptoms by applying MC903 to the ears of mice every other day for four weeks. Increased ear thickness, transepidermal water loss, number of scratching events, and serum IgE levels were observed in the MC903 model. Histological analysis revealed the infiltration of granulocytes and CD3-positive T cells and an increase in mast cells in the dermis. Furthermore, analyses of mRNA and protein expression in ear tissue revealed increased expression of thymic stromal lymphopoietin, IL-4, IL-13, and IL-33, which are involved in type 2 inflammation. All these changes were observed within two weeks after the initial application of MC903 and thereafter persisted throughout the experimental period. In conclusion, our data indicate that the long-term application of MC903 prolongs the duration of the three major symptoms of AD.